Contra: “New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation”

Claudia Stöllberger; Josef Finsterer

doi:10.1160/TH13-03-0246

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2013; 110(03): 496-500
DOI: 10.1160/TH13-03-0246

Pro/Contra Article

Schattauer GmbH

Contra: “New oral anticoagulants should not be used as 1^st choice for secondary stroke prevention in atrial fibrillation”

Authors

Claudia Stöllberger

¹Krankenanstalt Rudolfstiftung, Vienna, Austria
Josef Finsterer

¹Krankenanstalt Rudolfstiftung, Vienna, Austria

Abstract

Full Text

References

References
1 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009; 361: 1139-1151.
2 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011; 365: 883-891.
3 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011; 365: 981-992.
4 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
5 You JJ, Singer DE, Howard PA. et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e531S-e575S.
6 Wann LS, Curtis AB, Ellenbogen KA. et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011; 57: 1330-1337.
7 Heidbuchel H, Verhamme P, Alings M. et al. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013. Epub ahead of print
8 Ntaios G, Papavasileiou V, Diener HC. et al. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 2012; 43: 3298-3304.
9 Easton JD, Lopes RD, Bahit MC. et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11: 503-511.
10 Stöllberger C, Finsterer J. Concerns about storage and application of dabigatran and rivaroxaban. Eur J Clin Pharmacol 2013; 69: 739-740.
11 Lillo-Le Louët A, Wolf M, Soufir L. et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: Implications for emergency surgery and resuscitation. Thromb Haemost 2012; 08: 583-585.
12 Hart RG, Diener HC, Yang S. et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43: 1511-1517.
13 Mant J, Hobbs FD, Fletcher K. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
14 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
15 Matute MC, Guillán M, García-Caldentey J. et al. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 2011; 106: 178-179.
16 Stöllberger C, Rakusan S, Wimpissinger FT. et al. Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention. Thromb Haemost 2012; 108: 579-581.
17 Höllerl F, Stöllberger C, Finsterer J. Renal function, P-gp-affecting drugs and new anticoagulants for stroke prevention. Int J Cardiol. 2013. Epub ahead of print
18 Hansen ML, Sørensen R, Clausen MT. et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433-1441.
19 De Smedt A, De Raedt S, Nieboer K. et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis 2010; 30: 533-534.
20 Dhamoon MS, Tai W, Boden-Albala B. et al. Risk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study. Stroke 2007; 38: 1752-1758.
21 Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402.
22 Rose AJ, Hylek EM, Ozonoff A. et al. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes 2011; 04: 22-29.
23 Wallentin L, Yusuf S, Ezekowitz MD. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
24 Wallentin L, Lopes RD, Hanna M. et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted INR control for stroke prevention in atrial fibrillation. Circulation. 2013. Epub ahead of print
25 Heneghan C, Ward A, Perera R. et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012; 379: 322-334.